227 related articles for article (PubMed ID: 29669863)
1. Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.
He X; Kläsener K; Iype JM; Becker M; Maity PC; Cavallari M; Nielsen PJ; Yang J; Reth M
EMBO J; 2018 Jun; 37(11):. PubMed ID: 29669863
[TBL] [Abstract][Full Text] [Related]
2. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.
Cragg MS; Chan HT; Fox MD; Tutt A; Smith A; Oscier DG; Hamblin TJ; Glennie MJ
Blood; 2002 Nov; 100(9):3068-76. PubMed ID: 12384401
[TBL] [Abstract][Full Text] [Related]
3. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
4. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
5. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.
Varano G; Raffel S; Sormani M; Zanardi F; Lonardi S; Zasada C; Perucho L; Petrocelli V; Haake A; Lee AK; Bugatti M; Paul U; Van Anken E; Pasqualucci L; Rabadan R; Siebert R; Kempa S; Ponzoni M; Facchetti F; Rajewsky K; Casola S
Nature; 2017 Jun; 546(7657):302-306. PubMed ID: 28562582
[TBL] [Abstract][Full Text] [Related]
6. Integration of activatory and inhibitory signals in human B-cells.
Sármay G; Koncz G; Gergely J
Immunol Lett; 1996 Dec; 54(2-3):93-100. PubMed ID: 9052860
[TBL] [Abstract][Full Text] [Related]
7. Cd19-dependent activation of Akt kinase in B-lymphocytes.
Otero DC; Omori SA; Rickert RC
J Biol Chem; 2001 Jan; 276(2):1474-8. PubMed ID: 11042164
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K; Bai B; Hilden VI; Bollum LK; Våtsveen TK; Munthe LA; Smeland EB; Irish JM; Wälchli S; Myklebust JH
J Immunol; 2022 Nov; 209(10):2042-2053. PubMed ID: 36426942
[TBL] [Abstract][Full Text] [Related]
9. CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.
Padmore L; An S; Gunby RH; Kelly K; Radda GK; Knox KA
Cell Immunol; 1997 May; 177(2):119-28. PubMed ID: 9178638
[TBL] [Abstract][Full Text] [Related]
10. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
12. The IgG1 B-cell receptor provides survival and proliferative signals analogue to the Igα but not the Igβ co-receptor.
Song J; Uyttersprot N; Classen S; Waisman A
Eur J Immunol; 2016 Aug; 46(8):1878-86. PubMed ID: 27218486
[TBL] [Abstract][Full Text] [Related]
13. LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.
Curnock AP; Knox KA
Cell Immunol; 1998 Aug; 187(2):77-87. PubMed ID: 9732695
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Buhl AM; Cambier JC
J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation.
Fuentes-Pananá EM; Bannish G; Karnell FG; Treml JF; Monroe JG
J Immunol; 2006 Dec; 177(11):7913-22. PubMed ID: 17114463
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between SHP-2, phosphatidyl inositol 3-kinase and phosphoinositol 5-phosphatase in the Fc gamma RIIb mediated B cell regulation.
Sármay G; Koncz G; Pecht I; Gergely J
Immunol Lett; 1999 May; 68(1):25-34. PubMed ID: 10397152
[TBL] [Abstract][Full Text] [Related]
17. CD19 differentially regulates BCR signalling through the recruitment of PI3K.
Xu Y; Fairfax K; Light A; Huntington ND; Tarlinton DM
Autoimmunity; 2014 Nov; 47(7):430-7. PubMed ID: 24953501
[TBL] [Abstract][Full Text] [Related]
18. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.
Sander S; Calado DP; Srinivasan L; Köchert K; Zhang B; Rosolowski M; Rodig SJ; Holzmann K; Stilgenbauer S; Siebert R; Bullinger L; Rajewsky K
Cancer Cell; 2012 Aug; 22(2):167-79. PubMed ID: 22897848
[TBL] [Abstract][Full Text] [Related]
19. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
[TBL] [Abstract][Full Text] [Related]
20. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Kharas MG; Janes MR; Scarfone VM; Lilly MB; Knight ZA; Shokat KM; Fruman DA
J Clin Invest; 2008 Sep; 118(9):3038-50. PubMed ID: 18704194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
